Background The 2010 rheumatoid arthritis (RA) classification criteria are intended for research purposes and of the disease not diagnostic purposes. It is however a tool which clinicians commonly use in everyday practice when evaluating patients with arthritis. clearly stated that synovitis should be better explained by another disease. However, some who classified as seronegative RA might stil...

The structure of β-molybdenum dichloride is compared with that of TcCl(2) using EXAFS spectroscopy. For TcCl(2), the Tc atom is surrounded by Tc atoms at 2.13(2), 3.45(3), 3.79(4), and 4.02(4) Å. For β-MoCl(2), the Mo is surrounded by Mo atoms at 2.21(2), 2.91(3), and 3.83(4) Å. The latter distances are consistent with the presence of an [Mo(4)Cl(12)] unit in the solid state, one constituted b...

Objective: Previous studies have examined the role of sensory nerves and neural mediators in symmetrical joint inflammation and autoimmunity in rheumatoid arthritis (RA). In this study, we sought to examine the association between capsaicin skin test and disease activity in RA patients. Materials and Methods: Eighty RA patients (case group) and 20 healthy volunteers were enrolled in this experi...

In the crystal structure of the title compound, C(10)H(22)N(2)O(4) (2+)·2Cl(-) or (H(2)Me(2)eddp)Cl(2) (H(2)Me(2)eddp(2+) is the dimethyl N,N'-di-3-propane-carboxylato-ethane-1,2-diyldiimin-ium cation), the packing is stabilized by an infinite two-dimensional ⋯Cl⋯H-N-H⋯Cl⋯ hydrogen-bonding network. In addition, short C-H⋯Cl contacts are observed.

In patients with rheumatoid arthritis (RA) and an incomplete response to methotrex-ate, does the addition of biological agents or newer, disease-modifying antirheumatic drugs (DMARDs) to methotrexate prompt a more complete response than does the addition of placebo? D a t a s o u r c e s An existing systematic review was updated. Additional studies were identified by searching MEDLINE (July 199...

INTRODUCTION Combinations of disease-modifying anti-rheumatic drugs (DMARDs) are increasingly used to treat rheumatoid arthritis (RA). Early trials showed their toxicity while recent trials suggest superior efficacy. Trials of DMARD combinations have enrolled different types of patient (early or established RA), used different designs (step-up, parallel or step-down) and utilized a range of out...